EGEIRO PHARMA
Open bankruptcyA bankruptcy procedure is open for EGEIRO PHARMA according to publications in the Belgian State Gazette; curator: PIERRE-EMMANUEL CORNIL.
Summary
The 2023 annual accounts show equity of €6.0m and a net result of -€1.6m.
Are you a creditor?
Open bankruptcy
Source: Belgian Official Gazette
If this company owes you money, you are not paid automatically: you file your claim yourself, within the deadline the judgment sets.
The procedure
- Court
- Enterprise Court of Hainaut, Charleroi division
- Declared bankrupt
- 17 March 2025
- Supervising judge
- Patrick Fautre
- Official Gazette
- 21-03-2025 (pdf) ↗search the document for 2025/111887
Deadlines
- Appeal or third-party opposition until
- passed on 5 April 2025Fifteen days after the publication in the Official Gazette.art. XX.108 CEL
- File the claim in RegSol until
- passed on 16 April 2025art. XX.104 and XX.155 CEL
- First verification report
- passed on 14 May 2025Goods that belong to you, such as those delivered under retention of title, are reclaimed before this day.art. XX.104 and XX.194 CEL
- Late claim until
- passed on 17 March 2026Late, you share only in what has not been paid out yet, and the costs are yours.art. XX.165 CEL
Curator
- Pierre-Emmanuel CornilRue De Gozee, 137, 6110 Montigny-Le-Tilleulpe.cornil@codeca.be
What to do now
- Do not deliver on credit any more without an agreement with the curator.
- Gather your documents: invoices, purchase orders, contract, delivery notes and reminders.
- File your proof of claim in RegSol (regsol.be), yourself with eID or itsme, or through your lawyer. State principal, interest and costs separately, and any preferential right you hold.
- Delivered under retention of title? Reclaim your goods before the first report on the verification of claims.
- Ask your accountant about the VAT on the unpaid invoices: in a bankruptcy it can be recovered under conditions.
- Follow the file in RegSol: the verification report (admitted or disputed) and the curator's reports appear there.
The deadlines above come from the publication of the judgment. Check them in RegSol before you file anything; a passed deadline no longer applies.
File a claim in RegSol ↗
Watch
Follow this bankruptcy: you are alerted when it is closed or reversed.
General information, not legal advice. If in doubt, the curator, your lawyer or your accountant can help.Creditor guide for this company
Embed in an article
Writing about this bankruptcy? Put the card of EGEIRO PHARMA in your article: name, enterprise number, its status in the KBO and the latest annual accounts, with a link to this dossier.
Preview
The preview appears here.
- Stays current: the status follows the register, the figures are those of the latest filed accounts. No Checked score or verdict.
- Light on your page: one small script and one data request, also answered from a cache; no cookies, no tracking.
- Where scripts do not run (a newsletter, a feed reader) a plain link remains.
Signals
Three signals. The signal on the left, the evidence on the right.
+raises risk○neutral
neutral · Filed after the deadline
The financial year that closed on 31-12-2023 was due by 31-07-2024 and was filed on 08-08-2024, 8 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 6 filingsDeviation from the deadline
2025
not confirmed
2024
not filed
2023
8 d late
2022
55 d early
2021
33 d early
2020
40 d early
2019
14 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 5 accounts on average 27 days before the deadline; the sector median for financial year 2024 is 22 days before the deadline, and 27% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
Who ran this company, and where was it based, on a date before the end?Company as of a date Is the registered address a letterbox address or a business centre?Addresses Are there other customers at risk in your own list?Process a list How is the Manufacture of chemicals and chemical products sector doing?Sector figures
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2023, full schema
Turnover
€117,839▲ 25.3%
2022 · €94,037
EBIT margin
-1845.8%▲ 1107.0pp
2022 · -2952.8%
Net result
-€1.6m▲ 32.2%
2022 · -€2.3m
Working capital
€1.2m▼ 52.9%
2022 · €2.5m
Trend over the years
In euros
In per cent
Ratio
In full-time equivalents (FTE)
In euros
No line ticked in this group.
In per cent
No line ticked in this group.
Ratio
No line ticked in this group.
In full-time equivalents (FTE)
No line ticked in this group.
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 20, Manufacture of chemicals and chemical products, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20192020202120222023
Turnover€12,348€94,037▲ 662%€117,839▲ 25.3%
Operating result-€95,325▲ 24.0%-€401,200▼ 321%-€1.7m▼ 331%-€2.8m▼ 60.6%-€2.2m▲ 21.7%
Net result-€98,933▲ 23.0%-€388,463below the sector's middle half▼ 293%-€1.3mbelow the sector's middle half▼ 245%-€2.3mbelow the sector's middle half▼ 72.7%-€1.6mbelow the sector's middle half▲ 32.2%
EBIT margin-14001.5%-2952.8%▲ 11048.7pp-1845.8%▲ 1107.0pp
Equity€1.5m▲ 15.5%€3.4mwithin the sector's middle half▲ 119%€9.6mwithin the sector's middle half▲ 184%€7.5mwithin the sector's middle half▼ 22.0%€6.0mwithin the sector's middle half▼ 19.6%
Total assets€2.1m▲ 26.4%€5.1mwithin the sector's middle half▲ 145%€11.5mwithin the sector's middle half▲ 124%€9.5mwithin the sector's middle half▼ 17.0%€7.5mwithin the sector's middle half▼ 20.7%
Debt€539,739▲ 73.9%€1.7m▲ 218%€1.8m▲ 4.9%€2.0m▲ 9.8%€1.5m▼ 25.0%
Working capital€358,168▼ 54.1%€1.3mwithin the sector's middle half▲ 274%€5.3mwithin the sector's middle half▲ 294%€2.5mwithin the sector's middle half▼ 52.9%€1.2mwithin the sector's middle half▼ 52.9%
Solvency74.1%▼ 7.1pp66.4%within the sector's middle half▼ 7.8pp84.2%above the sector's middle half▲ 17.9pp79.2%above the sector's middle half▼ 5.1pp80.3%above the sector's middle half▲ 1.1pp
Current ratio2.90▼ 1.632.32within the sector's middle half▼ 0.586.96above the sector's middle half▲ 4.643.31above the sector's middle half▼ 3.653.45above the sector's middle half▲ 0.14
Return on assets (ROA)-4.7%▲ 3.0pp-7.6%below the sector's middle half▼ 2.9pp-11.7%below the sector's middle half▼ 4.1pp-24.4%below the sector's middle half▼ 12.7pp-20.8%below the sector's middle half▲ 3.5pp
Staff (FTE)4▲ 11.1%4.9below the sector's middle half▲ 22.5%7.7below the sector's middle half▲ 57.1%11.9below the sector's middle half▲ 54.5%7.5below the sector's middle half▼ 37.0%
above
within
below
the middle half (P25 to P75) of NACE 20, Manufacture of chemicals and chemical products, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2020 Net result -293% on 2019. The accounts now follow the full schema, last year the micro schema.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €2.2m in 2023 against €2.8m in 2022; the loss shrinks.
Balance-sheet composition
2023 in colour, 2022 as the grey bar beneath
Assets €7.1m
Fixed assets
€5.4m ▲ 2.4%
Current assets
€1.6m ▼ 53.7%
Equity and liabilities €7.5m
Equity
€6.0m ▼ 19.6%
Debt
€1.5m ▼ 25.0%
Debt's share of the balance-sheet total falls from 20.8% to 19.7%. Equity and debt are lower.
Key figures and ratios
EBITDA
-€1.1m▲
2022 · -€1.9m
Cash flow
-€506,698▲
2022 · -€1.4m
Quick ratio
3.19▼
2022 · 3.23
Debt to equity
0.25▼
2022 · 0.26
ROE
-26.0%▲
2022 · -30.8%
Interest coverage
-40.28▲
2022 · -62.25
Debt ≤ 1 year
€477,493▼
2022 · €1.1m
Debt > 1 year
€1.0m▲
2022 · €897,058
Income taxes
-€45,766▼
2022 · -€34,030
Staff costs
€770,425▼
2022 · €1.1m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | €2.2m | €2.0m | €1.3m | ▼ 36.6% |
| Turnover70 | - | - | €12,348 | €94,037 | €117,839 | ▲ 25.3% |
| Change in stocks of work in progress, finished goods and contracts in progress71 | - | - | €54,843 | €144,524 | -€8,817 | ▼ 106% |
| Own construction capitalised72 | - | - | €1.9m | €1.5m | €960,216 | ▼ 36.3% |
| Other operating income74 | - | - | €196,327 | €252,615 | €197,348 | ▼ 21.9% |
| Operating charges60/66A | - | - | €3.9m | €4.8m | €3.4m | ▼ 27.9% |
| Goods for resale, raw materials and consumables60 | - | - | €63,972 | €211,396 | €74,588 | ▼ 64.7% |
| Purchases600/8 | - | - | €206,459 | €146,696 | €115,734 | ▼ 21.1% |
| Change in stocks: decrease (increase)609 | - | - | -€142,487 | €64,700 | -€41,146 | ▼ 164% |
| Services and other goods61 | - | - | €2.5m | €2.3m | €1.5m | ▼ 34.9% |
| Remuneration, social security and pensions62 | - | - | €762,085 | €1.1m | €770,425 | ▼ 31.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €6,484 | €46,399 | €558,294 | €908,651 | €1.1m | ▲ 17.1% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | €186,141 | €0 | ▼ 100% |
| Other operating charges640/8 | - | - | €1,303 | €3,297 | €7,226 | ▲ 119% |
| Gross operating margin9900 | €232,543 | - | - | - | - | - |
| Operating profit (loss)9901 | -€95,325 | -€401,200 | -€1.7m | -€2.8m | -€2.2m | ▲ 21.7% |
| Financial income75/76B | - | - | €310,197 | €473,836 | €593,758 | ▲ 25.3% |
| Recurring financial income75 | €4,321 | €37,146 | €310,197 | €473,836 | €593,758 | ▲ 25.3% |
| Income from financial fixed assets750 | - | - | €9,481 | €10,067 | €10,602 | ▲ 5.3% |
| Income from current assets751 | - | - | - | - | €10,861 | - |
| Other financial income752/9 | - | - | €300,716 | €463,768 | €572,296 | ▲ 23.4% |
| Financial charges65/66B | - | - | €49,109 | €46,792 | €35,124 | ▼ 24.9% |
| Recurring financial charges65 | €7,421 | €24,899 | €49,109 | €46,792 | €35,124 | ▼ 24.9% |
| Debt charges650 | - | €21,591 | €26,452 | €30,009 | €27,584 | ▼ 8.1% |
| Other financial charges652/9 | - | - | €22,657 | €16,782 | €7,540 | ▼ 55.1% |
| Profit (loss) for the period before taxes9903 | -€98,426 | -€388,953 | -€1.5m | -€2.3m | -€1.6m | ▲ 31.2% |
| Income taxes67/77 | €507 | -€490 | -€126,974 | -€34,030 | -€45,766 | ▼ 34.5% |
| Taxes670/3 | - | - | €2,596 | €13,591 | €1,602 | ▼ 88.2% |
| Tax adjustments and reversals of tax provisions77 | - | - | €129,570 | €47,621 | €47,369 | ▼ 0.5% |
| Profit (loss) for the period9904 | -€98,933 | -€388,463 | -€1.3m | -€2.3m | -€1.6m | ▲ 32.2% |
| Profit (loss) for the period to be appropriated9905 | -€98,933 | -€388,463 | -€1.3m | -€2.3m | -€1.6m | ▲ 32.2% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €2.1m | €5.1m | €11.5m | €9.5m | €7.5m | ▼ 20.7% |
| Formation expenses20 | - | - | €818,975 | €635,415 | €451,855 | ▼ 28.9% |
| Fixed assets21/28 | €1.5m | €2.8m | €4.5m | €5.3m | €5.4m | ▲ 2.4% |
| Intangible fixed assets21 | €1.5m | €2.6m | €4.3m | €5.1m | €5.2m | ▲ 2.5% |
| Tangible fixed assets22/27 | €9,695 | €24,600 | €29,841 | €28,578 | €21,686 | ▼ 24.1% |
| Plant, machinery and equipment23 | - | - | €20,401 | €23,064 | €19,816 | ▼ 14.1% |
| Furniture and vehicles24 | - | - | €9,440 | €5,514 | €1,870 | ▼ 66.1% |
| Financial fixed assets28 | €11,149 | €162,683 | €183,489 | €193,556 | €200,790 | ▲ 3.7% |
| Affiliated companies280/1 | - | - | €171,564 | €181,631 | €192,233 | ▲ 5.8% |
| Participating interests280 | - | - | €8,749 | €8,749 | €8,749 | = |
| Amounts receivable281 | - | - | €162,815 | €172,882 | €183,484 | ▲ 6.1% |
| Other financial fixed assets284/8 | - | - | €11,925 | €11,925 | €8,557 | ▼ 28.2% |
| Amounts receivable and cash guarantees285/8 | - | - | €11,925 | €11,925 | €8,557 | ▼ 28.2% |
| Current assets29/58 | €546,202 | €2.4m | €6.2m | €3.6m | €1.6m | ▼ 53.7% |
| Stocks and contracts in progress3 | - | - | €197,330 | €91,013 | €123,342 | ▲ 35.5% |
| Stocks30/36 | - | - | €197,330 | €91,013 | €123,342 | ▲ 35.5% |
| Raw materials and consumables30/31 | - | - | €25,607 | €0 | - | - |
| Work in progress32 | - | - | €45,576 | €13,226 | €4,409 | ▼ 66.7% |
| Finished goods33 | - | - | €9,268 | €0 | - | - |
| Goods purchased for resale34 | - | - | €116,880 | €77,787 | €118,933 | ▲ 52.9% |
| Amounts receivable within one year40/41 | €318,273 | €90,863 | €279,243 | €235,098 | €334,308 | ▲ 42.2% |
| Trade receivables40 | - | - | €6,916 | €34,019 | €18,228 | ▼ 46.4% |
| Other amounts receivable41 | - | - | €272,327 | €201,079 | €316,079 | ▲ 57.2% |
| Cash at bank and in hand54/58 | €81,429 | €2.2m | €5.6m | €3.2m | €1.1m | ▼ 64.0% |
| Deferred charges and accrued income490/1 | - | - | €47,659 | €48,385 | €42,559 | ▼ 12.0% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €2.1m | €5.1m | €11.5m | €9.5m | €7.5m | ▼ 20.7% |
| Equity10/15 | €1.5m | €3.4m | €9.6m | €7.5m | €6.0m | ▼ 19.6% |
| Contributions10/11 | €134,905 | €248,930 | €10.2m | €10.2m | €10.2m | = |
| Capital10 | - | - | €322,394 | €322,394 | €322,394 | = |
| Issued capital100 | - | - | €322,394 | €322,394 | €322,394 | = |
| Outside capital11 | - | - | €9.9m | €9.9m | €9.9m | = |
| Share premium1100/10 | - | - | €9.9m | €9.9m | €9.9m | = |
| Profit (loss) carried forward14 | -€227,354 | -€615,817 | -€2.0m | -€4.3m | -€5.8m | ▼ 36.8% |
| Investment grants15 | - | - | €1.4m | €1.6m | €1.7m | ▲ 6.1% |
| Amounts payable17/49 | €539,739 | €1.7m | €1.8m | €2.0m | €1.5m | ▼ 25.0% |
| Amounts payable after more than one year17 | €349,243 | €699,100 | €909,568 | €897,058 | €1.0m | ▲ 11.5% |
| Financial debts170/4 | - | - | €909,568 | €897,058 | €1.0m | ▲ 11.5% |
| Subordinated loans170 | - | - | €62,500 | €37,500 | €12,500 | ▼ 66.7% |
| Other loans174 | - | - | €847,068 | €859,558 | €988,100 | ▲ 15.0% |
| Amounts payable within one year42/48 | €188,033 | €1.0m | €884,468 | €1.1m | €477,493 | ▼ 55.6% |
| Current portion of amounts payable after more than one year42 | - | - | €92,055 | €151,033 | €159,267 | ▲ 5.5% |
| Trade debts44 | €76,493 | €285,097 | €540,165 | €136,156 | €131,615 | ▼ 3.3% |
| Suppliers440/4 | - | - | €540,165 | €136,156 | €131,615 | ▼ 3.3% |
| Taxes, remuneration and social security45 | - | - | €173,004 | €239,943 | €100,527 | ▼ 58.1% |
| Taxes450/3 | - | - | €16,674 | €28,528 | €0 | ▼ 100% |
| Remuneration and social security454/9 | - | - | €156,330 | €211,415 | €100,527 | ▼ 52.5% |
| Other amounts payable47/48 | - | - | €79,245 | €548,415 | €86,084 | ▼ 84.3% |
| Accrued charges and deferred income492/3 | - | - | €9,800 | €8,045 | €6,900 | ▼ 14.2% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€98,933 | -€388,463 | -€1.3m | -€2.3m | -€1.6m | ▲ 32.2% |
| + Depreciation and write-downs630 | €6,484 | €46,399 | €558,294 | €908,651 | €1.1m | ▲ 17.1% |
| Operating cash flow (approximation) | -€92,449 | -€342,065 | -€782,556 | -€1.4m | -€506,698 | ▲ 64.0% |
| Investment in fixed assets (approximation) | - | -€1.3m | -€2.3m | -€1.7m | -€1.2m | ▲ 31.4% |
| Change in cash | - | €2.1m | €3.5m | -€2.4m | -€2.0m | ▲ 16.6% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
21-03
Bankruptcy
Opening
Tribunal de l’entreprise du Hainaut, division Charleroi · event 17-03-2025
2024
08-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 8 days late
2023
06-06
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
31-12
Financial
Weakest financial yearnet -€2.3m
Net result drops to -€2.3m, the lowest in the series.
28-06
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
31-12
Financial
Liquidity triplescurrent ratio 6.96
Current ratio from 2.32 to 6.96; short-term debt falls from €1.0m to €884,468.
31-12
Financial
Equity above €5mEq €9.6m ▲184%
Equity rises from €3.4m to €9.6m.
21-06
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
31-12
Financial
Equity above €2mEq €3.4m ▲119%
Equity rises from €1.5m to €3.4m.
17-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
28-06
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
SignalFinancial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 24 acts read
About the unread acts
We know of 24 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
24 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Charleroi · 2 establishment units since 2017
Ground area
5,140 m²
Building footprint
2,837 m²
Volume, LiDAR
19,891 m³
2 parcels, Brussels, Wallonia · tallest building 17.9 m, ±2 floors. Linked by address, not a title deed.
4
companies at this address
See who is registered here
2 establishment units
TheraVet
since 20172.270.356.165
TheraVet
since 20182.299.585.928
2 parcels
Wallonia
1
(50%)
Brussels
1
(50%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52028B0315/18E000 | Wallonia | 2,954 m² | 1 · 670 m² | 10.0 m · 2 fl. |
| 21307F0170/00S002 | Brussels | 2,186 m² | 1 · 2,167 m² | 17.9 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Insolvency mandates
1 mandate| Role | Name | Tenure |
|---|---|---|
| Curator | PIERRE-EMMANUEL CORNIL RUE DE GOZEE, 137,
6110 MONTIGNY-LE-TILLEUL |
17-03-2025 → present |
Structure & network
Owners and holdings
3 owners · 1 holdingOwners 3
-
11.4%
-
5%
- Sourceaccounts GLOB-CO 20225%
Holdings 1
- THERAVET US A, INC (Corporation)USsubsidiarySourceown accounts 2023Equity -USD 178,770Result -USD 9,301100%
According to the 2023 annual accounts of EGEIRO PHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Recognitions · licences · registrations
Legal Entity Identifier
984500804EBR3F1EFF71
Similar companies · same sector, comparable size
DEQUACHIM
BE 0425.182.969
Saint-Ghislain · Eq €6.0m
Vibrantz Minerals
BE 0403.045.985
Saint-Ghislain · Eq €5.7m
HYDROMETAL
BE 0427.416.939
Engis · Eq €6.9m
Loda
BE 0415.667.467
Beerse · Eq €4.8m
DE NEEF CONSTRUCTION CHEMICALS
BE 0440.092.166
Heist-op-den-Berg · Eq €8.1m
Of 63 companies in sector 20130 we hold annual accounts for 47. 23 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded22-11-2017
Fiscal year end31-12
Activities, NACEBEL 2025
20130Manufacture of chemicals and chemical products
E-invoicing
Not found in the Peppol register
No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.
Register as of 30 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
General meetings
2 convocationsExtraordinary general meeting
Agenda
figure ci-dessous. A. Procédure de sonnette d’alarme 1. Prise de connaissance du fait que l’actif net de la Société est réduit à un montant inférieur au quart du capital - Prise de connaissance du rapport du conseil d’administration sur les mesures proposées
Ordinary general meeting
Agenda
figure ci-dessous. 1. Délibération sur le rapport annuel du conseil d’administration ayant trait à l’exercice social clôturé le 31 décembre 2023 et sur le rapport du commissaire ayant trait à l’exercice social clôturé le 31 décembre 2023 Commentaire sur ce point de l’ordre du jour : le conseil d’adminis- tration prie l’assemblée générale des actionnaires de prendre note du rapport annuel du conseil d’administration ayant trait à l’exercice social clôturé le 31 décembre 2023, et du rapport du commissaire ayant trait à l’exercice social clôturé le 31 décembre 2023. 2. Délibération sur les comptes annuels ayant trait à l’exercice social clôturé le 31 décembre 2023, et sur l’affectation du résul ...